Etrasimod Shows Promise for Atopic Dermatitis

(MedPage Today) -- The investigational oral drug etrasimod may disrupt multiple pathways that cause acute and chronic disease phases of atopic dermatitis by disrupting sphingosine 1-phosphate receptor 1 (S1P1).
At the American Academy of Dermatology...